Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Depreciation" stands at 5.40 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 03/31/2019.
Novartis AG's third quarter result of 1.36 Billion USD for the item "Depreciation" represents an increase of 8.60 percent compared to it's second quarter result.
Also, Novartis AG's third quarter result of 1.36 Billion USD for the item "Depreciation" represents a decrease of -30.59 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of 5.40 Billion USD for the item "Depreciation" represents a decrease of -10.01 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -11.26 percent compared to the value the year prior.
The 1 year change in percent is -11.26.
The 3 year change in percent is -19.99.
The 5 year change in percent is -20.37.
The 10 year change in percent is -0.6437.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Depreciation | 905,699,262,464.00 |
![]() | Johnson & Johnson - Depreciation | 486,508,953,600.00 |
![]() | AbbVie Inc - Depreciation | 399,570,305,024.00 |
![]() | Roche Holding AG - Depreciation | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Depreciation | 280,205,508,085.11 |